Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 23 Mar 2022 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 7 Mar 2022 |
| Orion Corporation: Managers’ transactions – Jari Karlson | 3 Mar 2022 |
| Orion Corporation: Managers’ transactions – Liisa Hurme | 3 Mar 2022 |
| Orion Corporation: Managers’ transactions – Olli Huotari | 3 Mar 2022 |